Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BENCHMARK ELECTRONICS INCBHE · Entity 4343 | Director | May 12, 2021 | May 14, 2021 |
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Director | June 10, 2026 | June 12, 2026 |
| TransMedics Group, Inc.TMDX · Entity 4261 | Director | May 20, 2026 | May 22, 2026 |
| WATTS WATER TECHNOLOGIES INCWTS · Entity 44 | Director | August 03, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BENCHMARK ELECTRONICS INC
Report date May 12, 2021 · Filed May 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,489 |
Reported balance
After 2021-05-12 transaction · row 1
1 source rowRow 1 · 2021-05-12 · Grant · Acquired 5,200 · Balance 24,489 F1: These shares are represented by a restricted stock unit award bearing the right to receive Common Shares and are scheduled to vest one-year from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by a restricted stock unit award bearing the right to receive Common Shares and are scheduled to vest one-year from the date of grant.
OCULAR THERAPEUTIX, INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,933 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 14,000 · Balance 60,933 F1: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.74 · Expires 2036-06-09 | Direct | 44,000 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 44,000 · Balance 44,000 F2: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
F2: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
TransMedics Group, Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,981 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 2,922 · Balance 6,981 F1: Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
WATTS WATER TECHNOLOGIES INC
Report date August 03, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 21,670 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 456 · Balance 21,670 F1: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $160,000 by the closing stock price on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $160,000 by the closing stock price on the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARATANA THERAPEUTICS, INC.
Report date July 18, 2019 · Filed July 18, 2019
Section 16 reporting ended · disclosed 2019-07-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 1
1 source rowRow 1 · 2019-07-18 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.17 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-18 · Disposition to issuer · Disposed 13,237 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.27 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.84 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2)
F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration").
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.
F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 4, 2026 19:06 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 456 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-006921 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,670 F1 · shares: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $160,000 by the closing stock price on the grant date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:19 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001104659-26-073582 · tm2617745-2_4seq1.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2036-06-09 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:19 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073582 · tm2617745-2_4seq1.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,933 F1 · shares: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:15 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 2,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-236914 · ownership.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,981 F1 · shares: Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 05, 2025 Filed Aug 5, 2025 15:56 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 516 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-007006 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,214 F1 · shares: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $130,000 by a 30-day trailing average stock price. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:25 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001104659-25-059389 · tm2517945-5_4seq1.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:25 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-059389 · tm2517945-5_4seq1.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,933 F1 · shares: On June 11, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 22:46 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 2,134 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077220 · ownership.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,059 F1 · shares: Consists of 2,134 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 05, 2024 Filed Aug 5, 2024 20:46 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 678 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-007870 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,698 F1 · shares: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $130,000 by a 30-day trailing average stock price. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 22:40 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $7.91 | $0.00 |
DisclosureSEC source: 0001104659-24-083099 · tm2420266-4_4seq1.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2034-07-23 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 22:40 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-083099 · tm2420266-4_4seq1.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,933 F1 · shares: On July 24, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 1,154 | $0.00 Strike: $137.53 | $0.00 |
DisclosureSEC source: 0000950170-24-065397 · ownership.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,154 Underlying: Common Stock · 1,154 shares Expires 2034-05-23 F2 · derivative.exercise_date: The option vests in full on the earlier of May 23, 2025 or the date of the 2025 annual meeting of the stockholders of the Issuer, subject to continued service. Read SEC document |
| May 23, 2024 Filed May 28, 2024 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 732 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-065397 · ownership.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,925 F1 · shares: Consists of 732 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 31, 2023 Filed Jul 31, 2023 20:57 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 713 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-007784 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,020 F1 · shares: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $130,000 by a 30-day trailing average stock price. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 23:05 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001104659-23-072403 · tm2318782-5_4seq1.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-06-13 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 23:05 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-072403 · tm2318782-5_4seq1.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,933 F1 · shares: On June 14, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 1,916 | $0.00 Strike: $71.33 | $0.00 |
DisclosureSEC source: 0000950170-23-024885 · ownership.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,916 Underlying: Common Stock · 1,916 shares Expires 2033-05-25 F2 · derivative.exercise_date: The option vests in full on the earlier of May 25, 2024 or the date of the 2024 annual meeting of the stockholders of the Issuer, subject to continued service. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 1,193 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-024885 · ownership.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,193 F1 · shares: Includes 1,193 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 19:03 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 1,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-009083 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,307 F1 · shares: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $130,000 by a three-month trailing average stock price. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 00:10 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 26,800 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001104659-22-073152 · tm2218958-6_4seq1.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 Underlying: Common Stock · 26,800 shares Expires 2032-06-15 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 00:10 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 8,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073152 · tm2218958-6_4seq1.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,933 F1 · shares: On June 16, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $28.12 | $0.00 |
DisclosureSEC source: 0000899243-22-021202 · doc4.xml · derivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant, June 1, 2023, or the date of the following annual meeting of shareholders of the Company. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 12:19 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001104659-21-118130 · tm2128101-3_4seq1.xml · derivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2031-09-19 F1 · derivative.exercise_date: Vests over three years, vesting 1/3 on each yearly anniversary of the date of grant. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 20:48 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 794 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-011021 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,288 F1 · shares: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $110,000 by a three-month trailing average stock price. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 21:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 2,250 | $0.00 Strike: $26.26 | $0.00 |
DisclosureSEC source: 0000899243-21-021342 · doc4.xml · derivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires 2031-05-27 F1 · derivative.exercise_date: The option vests as to one-third of the shares subject to the option on January 1, 2022 and in equal monthly installments as to the remainder of the shares for two years thereafter. Read SEC document |
| May 12, 2021 Filed May 14, 2021 16:40 UTC | BENCHMARK ELECTRONICS INC BHE · Entity 4343 | GrantCommon Stock | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032627 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,489 F1 · shares: These shares are represented by a restricted stock unit award bearing the right to receive Common Shares and are scheduled to vest one-year from the date of grant. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 22:57 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0000899243-21-000436 · doc4.xml · derivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-01-01 F1 · derivative.exercise_date: The option vests as to one-third of the shares subject to the option on the first anniversary of the date of grant and in equal monthly installments as to the remainder of the shares for two years thereafter. Read SEC document |
| July 27, 2020 Filed Jul 27, 2020 18:29 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 1,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-009965 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,494 F1 · shares: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $110,000 by a three-month trailing average stock price. Read SEC document |
| May 13, 2020 Filed May 14, 2020 19:04 UTC | BENCHMARK ELECTRONICS INC BHE · Entity 4343 | GrantCommon Stock | 7,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005968 · edgar.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,289 F1 · shares: These shares are represented by a restricted stock unit award bearing the right to receive Common Shares and are scheduled to vest one-year from the date of grant. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 14:04 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 1,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-010598 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,135 F1 · shares: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $110,000 by a twelve-month trailing average stock price. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:48 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001209191-19-042721 · doc4.xml · derivative · entry 7 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:48 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-19-042721 · doc4.xml · derivative · entry 6 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:48 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $6.84 | Not disclosed |
DisclosureSEC source: 0001209191-19-042721 · doc4.xml · derivative · entry 5 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:48 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0001209191-19-042721 · doc4.xml · derivative · entry 4 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:48 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $14.27 | Not disclosed |
DisclosureSEC source: 0001209191-19-042721 · doc4.xml · derivative · entry 3 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:48 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,237 | Not disclosed Strike: $21.17 | Not disclosed |
DisclosureSEC source: 0001209191-19-042721 · doc4.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,237 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:48 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-042721 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · shares: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3 · shares: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards. F1 · price: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · price: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 21:55 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-19-035638 · doc4.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-05 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 21:55 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035638 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:13 UTC | BENCHMARK ELECTRONICS INC BHE · Entity 4343 | GrantCommon Stock | 5,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-006265 · edgar.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,406 F1 · shares: These shares are represented by a restricted stock unit award bearing the right to receive Common Shares and are scheduled to vest one-year from the date of grant. Read SEC document |
| July 30, 2018 Filed Jul 31, 2018 16:20 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 1,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-012037 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,754 F1 · shares: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $100,000 by a twelve-month trailing average stock price. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 21:45 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001209191-18-044449 · doc4.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-07-26 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 21:45 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-044449 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 20:25 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 1,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-013079 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,398 F1 · kind: Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $100,000 by a twelve-month trailing average stock price. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 21:37 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0001209191-17-041738 · doc4.xml · derivative · entry 2 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-20 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 21:37 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041738 · doc4.xml · nonDerivative · entry 1 RAINES MERILEE · CIK 0001023869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.